OBJECTIVE: To confirm the cost savings in a randomized clinical trial of the Vermedx Diabetes Information System (hereafter referred to as the Diabetes Information System [DIS]) in independently collected data using claims paid by a managed care insurer for patients with and without DIS participation. STUDY DESIGN: Longitudinal analysis of paid claims with concurrent and historical controls from October 2002 through October 2007. METHODS: Using locally weighted smoothing functions and linear regression analysis before and after commencement of the DIS, we compared the total claims paid per member per month for 153 patients using the DIS versus 870 control patients. RESULTS: For DIS patients, paid claims increased at a rate of $8.30 (95% confidence interval [CI], $1.12-$15.48) per month before the DIS started compared with -$3.92 (95% CI, -$9.50 to $1.67) after commencement of the DIS (P = .008). For control patients, the slope changed from $6.80 (95% CI, $3.78-$9.82) to $3.16 (95% CI, -$1.06 to $7.38) (P = .17). After commencement of the DIS, the slope of the claims in the DIS group is significantly lower than that of the control group (-$3.92 vs $3.16, P = .046). The mean estimated savings range from $504 per patient in year 1 of operations to $3563 in year 4. The cumulative net savings reach $8134 in 4 years. CONCLUSIONS: Participation in the DIS is associated with substantial reductions in claims paid, net of the costs of the intervention. The cost savings reported in the randomized clinical trial of the DIS are reproduced in an independent data set.
RCT Entities:
OBJECTIVE: To confirm the cost savings in a randomized clinical trial of the Vermedx Diabetes Information System (hereafter referred to as the Diabetes Information System [DIS]) in independently collected data using claims paid by a managed care insurer for patients with and without DIS participation. STUDY DESIGN: Longitudinal analysis of paid claims with concurrent and historical controls from October 2002 through October 2007. METHODS: Using locally weighted smoothing functions and linear regression analysis before and after commencement of the DIS, we compared the total claims paid per member per month for 153 patients using the DIS versus 870 control patients. RESULTS: For DISpatients, paid claims increased at a rate of $8.30 (95% confidence interval [CI], $1.12-$15.48) per month before the DIS started compared with -$3.92 (95% CI, -$9.50 to $1.67) after commencement of the DIS (P = .008). For control patients, the slope changed from $6.80 (95% CI, $3.78-$9.82) to $3.16 (95% CI, -$1.06 to $7.38) (P = .17). After commencement of the DIS, the slope of the claims in the DIS group is significantly lower than that of the control group (-$3.92 vs $3.16, P = .046). The mean estimated savings range from $504 per patient in year 1 of operations to $3563 in year 4. The cumulative net savings reach $8134 in 4 years. CONCLUSIONS: Participation in the DIS is associated with substantial reductions in claims paid, net of the costs of the intervention. The cost savings reported in the randomized clinical trial of the DIS are reproduced in an independent data set.
Authors: S Trent Rosenbloom; Titus L Daniels; Thomas R Talbot; Taylor McClain; Robert Hennes; Shane Stenner; Sue Muse; Jim Jirjis; Gretchen Purcell Jackson Journal: J Am Med Inform Assoc Date: 2011-12-01 Impact factor: 4.497
Authors: Amber A W A van der Heijden; Martine C de Bruijne; Talitha L Feenstra; Jacqueline M Dekker; Caroline A Baan; Judith E Bosmans; Sandra D M Bot; Gé A Donker; Giel Nijpels Journal: BMC Health Serv Res Date: 2014-06-25 Impact factor: 2.655